1. Home
  2. CGEM vs TCPC Comparison

CGEM vs TCPC Comparison

Compare CGEM & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGEM
  • TCPC
  • Stock Information
  • Founded
  • CGEM 2016
  • TCPC 2012
  • Country
  • CGEM United States
  • TCPC United States
  • Employees
  • CGEM N/A
  • TCPC N/A
  • Industry
  • CGEM Biotechnology: Pharmaceutical Preparations
  • TCPC Finance/Investors Services
  • Sector
  • CGEM Health Care
  • TCPC Finance
  • Exchange
  • CGEM Nasdaq
  • TCPC Nasdaq
  • Market Cap
  • CGEM 955.5M
  • TCPC 766.9M
  • IPO Year
  • CGEM 2021
  • TCPC 2012
  • Fundamental
  • Price
  • CGEM $12.54
  • TCPC $9.05
  • Analyst Decision
  • CGEM Strong Buy
  • TCPC Hold
  • Analyst Count
  • CGEM 7
  • TCPC 7
  • Target Price
  • CGEM $31.67
  • TCPC $8.88
  • AVG Volume (30 Days)
  • CGEM 537.5K
  • TCPC 620.5K
  • Earning Date
  • CGEM 11-07-2024
  • TCPC 11-06-2024
  • Dividend Yield
  • CGEM N/A
  • TCPC 15.01%
  • EPS Growth
  • CGEM N/A
  • TCPC N/A
  • EPS
  • CGEM N/A
  • TCPC N/A
  • Revenue
  • CGEM N/A
  • TCPC $249,036,775.00
  • Revenue This Year
  • CGEM N/A
  • TCPC $26.61
  • Revenue Next Year
  • CGEM N/A
  • TCPC N/A
  • P/E Ratio
  • CGEM N/A
  • TCPC N/A
  • Revenue Growth
  • CGEM N/A
  • TCPC 21.38
  • 52 Week Low
  • CGEM $7.64
  • TCPC $7.71
  • 52 Week High
  • CGEM $30.19
  • TCPC $12.43
  • Technical
  • Relative Strength Index (RSI)
  • CGEM 31.78
  • TCPC 65.05
  • Support Level
  • CGEM $12.04
  • TCPC $8.90
  • Resistance Level
  • CGEM $17.50
  • TCPC $9.12
  • Average True Range (ATR)
  • CGEM 1.12
  • TCPC 0.22
  • MACD
  • CGEM -0.36
  • TCPC 0.06
  • Stochastic Oscillator
  • CGEM 9.15
  • TCPC 94.96

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

About TCPC BlackRock TCP Capital Corp.

BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.

Share on Social Networks: